John Reed, J&J’s EVP of innovative medicine
December 5, 2023 07:15 AM ESTUpdated 07:44 AM
R&D
Pharma

J&J promis­es 20 new drugs to back phar­ma growth through end of decade, as John Reed shares his plans

Drew Armstrong

Executive Editor

John­son & John­son is lay­ing out its drug de­vel­op­ment am­bi­tions un­der its new R&D chief, pro­ject­ing that it will bring in bil­lions of dol­lars in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times